HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IDYA
IDEAYA Biosciences, Inc.
There isn't enough reported data to score IDYA yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IDYA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
IDYA's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IDYA PE Valuation
IDYA has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IDYA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IDYA's losses to grow, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
IDYA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.46 | -$2.54 |
| Q2 2026 | -$1.91 | +$1.94 |
| Q1 2026 | -$1.57 | +$2.08 |
| Q4 2025 | -$1.28 | +$2.08 |
| Q3 2025 | -$1.92 | +$0.40 |
| Q2 2025 | -$3.85 | -$1.67 |
| Q1 2025 | -$3.65 | -$1.65 |
| Q4 2024 | -$3.36 | -$1.40 |
IDYA lost $4.46 per share over the past year, and its loss has widened in each of the last three quarters.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over IDYA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over IDYA on profitability, with a higher operating margin.
IDYA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.2M | -95% |
| Q4 2025 | $10.9M | +55% |
| Q4 2024 | $7M | +78% |
| Q4 2023 | $3.9M | -2.5% |
| Q3 2023 | $8M | -73% |
| Q2 2023 | $3.5M | -39% |
| Q1 2023 | $7.9M | -31% |
| Q4 2022 | $4M | +36% |
IDYA's revenue has slid since its 2025 peak: $10M last quarter, down 95% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1344% | -1396 points |
| Q2 2026 | -1381% | N/A |
| Q1 2026 | -1655% | N/A |
| Q4 2025 | -870% | +1190 points |
| Q3 2025 | 52% | N/A |
| Q4 2024 | -2059% | -990 points |
| Q4 2023 | -1069% | -411 points |
| Q3 2023 | -417% | -419 points |
IDYA's operating margin was −1344% last quarter, down 1396 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over IDYA on cash generation, producing positive trailing cash flow while its opponent burns cash.
IDYA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$93.8M | -166% |
| Q2 2026 | -$89.1M | -$25.9M |
| Q1 2026 | -$76.1M | -$14.5M |
| Q4 2025 | -$90.8M | +$31.9M |
| Q3 2025 | $142.2M | +$191.9M |
| Q2 2025 | -$63.1M | -$29.3M |
| Q1 2025 | -$61.7M | -$16.5M |
| Q4 2024 | -$122.8M | -$98.2M |
IDYA has burned cash in almost every quarter: −$350M over the past year, against −$105M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IDYA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IDYA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +12% | +10.9M shares |
| 1 year | +15% | +13.3M shares |
| 3 years | +83% | +46.7M shares |
| 5 years | +213% | +70.1M shares |
| Available history | +408% | +82.7M shares |
IDYA has 103M diluted shares, up 15% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IDYA Net Leverage
IDYA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IDYA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.2 | Neutral |
| Stochastic | 5.8 | Oversold |
IDYA's weekly RSI is 42 (neutral) and its Stochastic is 6 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IDYA PE vs Healthcare Sector
IDYA has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IDYA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $34.1 | 7.5% below |
| 20 week MA | $36.2 | 13% below |
| 50 week MA | $33.8 | 6.7% below |
| 100 week MA | $28.6 | 10% above |
| 200 week MA | $29.5 | 6.6% above |
IDYA has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
IDYA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.50 | $12.9 | +52% |
| 2021 | $12.9 | $23.4 | +81% |
| 2022 | $23.4 | $17.0 | -27% |
| 2023 | $17.0 | $35.6 | +109% |
| 2024 | $35.6 | $25.2 | -29% |
| 2025 | $25.2 | $35.2 | +40% |
| 2026 YTD | $35.2 | $31.5 | -11% |
IDYA has the edge over HIMS on returns for 2026, with the stronger performance.